DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Uber, Intel, Lyft, Shopify, Rivian and more
▼ + stars: | 2024-05-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +5 min

The company's overall revenue exceeded expectations, coming in at $10.13 billion versus analysts' estimate of $10.11 billion, per LSEG. Lyft – The ride-sharing company surged 5% after the company reported faster-than-expected growth in the first quarter. Lyft reported $1.28 billion in revenue, higher than the FactSet consensus of $1.16 billion. Arista Networks – Shares jumped 7% after the company reported better-than-expected first quarter results. Teva Pharmaceuticals — Shares advanced nearly 14% after the company reported better-than-expected revenue in the first quarter.

Persons: Lyft, FactSet, Rivian, Coupang, LSEG, Twilio, –, —, Samantha Subin, Tanaya Macheel, Michelle Fox, Alex Harring Organizations: Technologies, Revenue, LSEG, Intel, Department of Commerce, Huawei, Lyft, Electronic Arts, EA, Farfetch, Arista Networks –, Arista, Dutch Bros, Bros, Pharmaceuticals, Management Locations: China, Korea

☆ Earnings will drive the market next week — what we expect from 2 portfolio stocks
▼ + stars: | 2024-05-04 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

With the Fed, Apple earnings and the jobs report passing with flying colors this week, the runway to more gains looks a lot less cluttered. This past week was chock full of Club earnings: 12 portfolio companies, including Apple , delivered results. Analysts expect Wynn's earnings per share of $1.27 versus 29 cents a year ago when China was not fully back from Covid. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jerome Powell, we're, Jim Cramer, Jim, Apple, Eli Lilly, Estee Lauder, Stanley Black, Decker, Bausch, FactSet, It's, Bob Iger, Iger, Nelson Peltz, We're, Krystal, Berkshire Hathaway, Tyson, Jones Lang, Walt, Ferrari N.V, WK Kellogg, Wynn, Vishay, CRON, MARA, RICK, Ginkgo, Jim Cramer's, David Paul Morris Organizations: Federal Reserve, Apple, GE Healthcare, DuPont, Linde, Bausch Health, Coterra Energy, Club, Disney, Wynn Resorts, CNBC, Revenue, Vegas Sands, Cotai, Boston, Airlines, Krystal Biotech, Alpha Metallurgical Resources, Axsome Therapeutics, Tyson Foods, TSN, Bowlero Corp, CNA Financial Corp, CNA, Jones Lang LaSalle Incorporated, Technologies, Realty Income Corp, Lab, Teradata Corp, Technology, FMC Corporation, FMC, Paymentus Holdings, Shockwave, Vertex Pharmaceuticals, Goodyear Tire & Rubber Company, Simon Property Group, Sterling Construction Company, Apple Hospitality, Boise Cascade Corporation, BellRing Brands, Coty, COTY, Fidelity National Information Services Inc, Vornado Realty, Walt Disney Co, Holdings, Madrigal Pharmaceuticals, Nikola Corporation, BP, Rockwell Automation, MarketAxess Holdings, Jumia Technologies, GEO Group, Builders FirstSource Inc, Duke Energy Corp, WYNN, Rivian Automotive, Arista Networks, Occidental Petroleum Corp, Astera Labs, Bros, Flywire Corporation, B2Gold Corp, Kinross Gold Corp, Virgin Galactic Holdings, iRobot Corp, Electronic Arts Inc, McKesson Corp, ACM Research, Avadel Pharmaceuticals, Toyota Motor Corp, Emerson Electric Co, Perion, Editas, Brink's Company, Sinclair Corporation, New Fortress Energy, Starwood Property Trust, Animal Health, ELAN, Farms, IM Cannabis Corp, Fox Corporation, Formula One, Icahn Enterprises, Teva Pharmaceutical Industries, Arm Holdings plc, ARM, AMC Entertainment Holdings, Trade, AppLovin Corporation, Sciences Corp, SolarEdge Technologies, Roblox Corporation, GigaCloud Technology Inc, Warner Bros ., Properties Trust, Growers, Constellation Energy Group, Cronos, Fiverr, Solar Inc, EPAM Systems, Cedar Fair Entertainment, Digital Holdings, RCI Hospitality Holdings, Akamai Technologies, Semiconductor, Insulet Corp, NuScale Power Corporation, Ginkgo Bioworks Holdings, Bloom Energy Corporation, Construction, AMC Networks, CRH Public Ltd . Company, Jim Cramer's Charitable, Allen, Co . Media, Technology Conference, Bloomberg, Getty Locations: China, Eaton, Amazon, Covid, Macao, Vegas, Sun Valley , Idaho

☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.

Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S

Shanker also raised his price target to $80 from $75, suggesting nearly 34% downside from Friday's close. — Spencer Kimball 8:16 a.m.: Loop Capital upgrades Corteva, touts growth acceleration in 2025 Corteva's stronger-than-expected 2024 full-year guidance will jumpstart a period of strong growth, according to Loop Capital. The firm upgraded the agricultural chemicals company to buy from hold and increased its price target to $65 from $57. Analyst Jay Sole upgraded Urban to neutral from sell and upped his 12-month price target by $20 to $41. Kaufman's $183 price target indicates roughly 6.3% downside for shares, which have fallen more than 18% over the past year.

Persons: headwinds, Morgan Stanley downgrades XPO, Morgan Stanley, Ravi, Shanker, — Michelle Fox, Julien Dumoulin, Smith, Duke's, — Spencer Kimball, Chris Kapsch, Kapsch, Brian Evans, Cassie Chan, they'll, Chan, —, Jay Sole, URBN, Sole, Urban's, — Pia Singh, Filippo Falorni, Falorni, Hershey, Stanley, Pamela Kaufman, Kaufman's, Hershey's, Kaufman, Graham Doyle, Doyle, Piper Sandler, David Amsellem, Amsellem, Amsellam, Christopher Horvers, Jan, Horvers, Fred Imbert, Dan Levy, Levy Organizations: CNBC, Barclays, Automotive, JPMorgan, Corp, Bank of America, Bank of America downgrades Duke Energy, Duke Energy, Duke, Wall, America, UBS, Urban Outfitters, Free People, Urban, Citi, PepsiCo, Citi Research, Pepsi, Hershey, GE Healthcare Technologies, UBS GE Healthcare Technologies, Pharmaceutical, Teva Pharmaceutical, Federal, Barclays downgrades Rivian, Rivian Automotive, North American EV Locations: Bank of America downgrades, GEHC, David Amsellem U.S

☆ Stocks making the biggest moves premarket: Rivian, Rocket Lab, Hershey, Lowe's and more
▼ + stars: | 2024-02-12 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Rocket Lab — The stock rose around 1% after Citi reinstated coverage with a buy rating. Lowe's — The home improvement retailer added 1.7% after JPMorgan raised its rating on shares to overweight from neutral. Urban Outfitters — Shares rose more than 2% after an upgrade from UBS ahead of the retailer's fourth-quarter earnings release slated for this month. On Monday, Bank of America Securities reiterated a neutral rating on the stock, but noted leadership has "the playbook to turn things around." Marqeta — Shares of the card issuing technology company rose 6.5% premarket after a Bank of America upgrade to buy from neutral on Monday.

Persons: Hershey, Morgan Stanley, Jason Gursky, Piper Sandler, Lowe's, XPO, BofA, CNBC's Michelle Fox, Sarah Min, Tanaya Macheel Organizations: Citi, Space Development Agency, U.S ., Teva Pharmaceutical Industries, JPMorgan, Federal Reserve, UBS, Barclays, New York Community Bancorp, Bank of America Securities, Bank of America

☆ Stocks making the biggest moves midday: New York Community Bancorp, Diamondback Energy, VF Corp. and more
▼ + stars: | 2024-02-12 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Bank of America also reiterated its neutral rating on Monday, while noting that leadership has "the playbook to turn things around." Diamondback Energy — The shale producer jumped 9.4% after announcing its purchase of Endeavor Energy, the biggest private company that produces natural resources from the Permian Basin. CymaBay Therapeutics , Gilead — Shares of CymaBay soared 25.4% after Gilead agreed to buy the drug developer. The deal comes as Gilead, whose shares were up around 1% in Monday's session, looks to expand beyond HIV drugs. Marqeta — The credit card technology stock added 5.7% after a Bank of America upgrade to buy from neutral.

Persons: Gilead, Bracken Darrell, Trimble, —, Joe Ahlersmeyer, Piper Sandler, Teva, Samantha Subin, Sarah Min Organizations: New York Community Bancorp, Bank of America, Endeavor Energy, CymaBay Therapeutics, Gilead, VF Corp, Reuters, Mohawk Industries, Deutsche Bank, Citi, Space Development Agency, Teva Pharmaceutical —, JPMorgan, Nvidia Locations: Israel

☆ Teva Pharma CEO Richard Francis on Q4 earnings
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTeva Pharma CEO Richard Francis on Q4 earningsRichard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's recent divestiture, how easy it'll be to disentangle from part of its business, and more.

Persons: Richard Francis Organizations: Teva, Teva Pharmaceuticals

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ 10 of our stocks report earnings next week. Here's what we want to see from each
▼ + stars: | 2024-01-27 | by ( Zev Fima | ) www.cnbc.com time to read: +16 min

All three major averages posted gains for the third consecutive week, lifted by solid quarterly earnings and positive economic data. Earnings season ramps up next week, with five of the Super Six mega-cap stocks delivering results. Employment numbers are the most important economic data, with Friday's January nonfarm payrolls report carrying the most weight. The January ISM Manufacturing report on Thursday and December's factory orders report Friday are expected to show the sector still in contraction mode. But earnings and commentary this week from peer Sartorious made us encouraged about a return to growth in 2024.

Persons: nonfarm, December's, Sartorious, We've, Stanley Black, Decker, We're, We'd, Royal Philips, Crane, Woodward, ServisFirst, Cadence Bancorporation, CADE, Johnson, Phillips, Avery Dennison, Columbus McKinnon, Robinson, SIRI, Cardinal Health, Parker, DOV, Pitney Bowes, Ferrari N.V, CSW, COLM, W.W, Grainger, Dwight Co, Jim Cramer's, Jim Cramer, Jim, Tim Cook, Justin Sullivan Organizations: Gross, Procter, Gamble, Gillette, Super, Consumer, JPM Healthcare, Amazon, Microsoft, Honeywell, Aerospace, Solutions, Apple Watch, Masimo, Vision Pro, Franklin Resources, Resource Partners, Bank of Marin Bancorp, Bank7 Corp, Pacific Premier Bancorp Inc, Provident Financial Holdings, Dynex, Cliffs Inc, Nucor Corp, Whirlpool Corp, F5 Networks, Capital Southwest Corp, Harbors Investment Corp, Crane Co, Payne, Equity, Heartland Financial, Cadence, FinWise Bancorp, Five Star Bancorp, PotlatchDeltic Corporation, Sanmina Corporation, Pfizer, General Motors Corp, United Parcel Service, JetBlue Airways Corporation, Smith Corp, Marathon Petroleum Corp, HCA Healthcare, Oshkosh Corporation, SYSCO Corp, Danaher Corp, Johnson Controls, M.D.C . Holdings, Commvault Systems Inc, Hope Bancorp, Hubbell Incorporated, Malibu Boats, Polaris Industries, Inc, Camden National Corp, Cambridge Bancorp, Microsoft Corp, Starbucks Corp, Devices, Electronic Arts Inc, Juniper Networks, Stryker Corp, Lending, Canadian, Canadian Pacific Kansas City Limited, Mondelez, Chubb Corporation, Modine Manufacturing, Partners, Management, Hawaiian Holdings, Manhattan Associates, Unum Group, UNM, Axos, Enova, Boston Properties, Boeing Co, Novo Nordisk, Mastercard Inc, Roper Technologies, Boston Scientific Corporation, MarketAxess Holdings, Fisher, Aptiv PLC, Hess Corp, Nasdaq, United Microelectronics Corp, Rockwell Automation, Teva Pharmaceutical Industries, Ltd, Avery, Avery Dennison Corp, Extreme Networks, Otis Worldwide Corporation, OTIS, Columbus, Columbus McKinnon Corp, Central Pacific Financial Corp, Brinker International, Fortive Corporation, Qualcomm, Technology, Metlife, Hanover Insurance, Barn Holdings, CONMED Corporation, DLH Holdings Corp, Meritage Homes Corporation, Honeywell International, Eaton Corp, Altria, Royal Caribbean Cruises Ltd, Merck, Co, Enterprise Products Partners, Dorian LPG, SiriusXM Holdings, Cardinal, Hannifin Corporation, Allegheny Technologies Incorporated, Tractor Supply Company, Trane Technologies, Dover Corp, Huntington Ingalls Industries, Brunswick Corporation, Dickinson, Canada Goose Holdings, Kirby Corp, WEC Energy Group, WestRock Company, Allegro MicroSystems, Ball Corporation, Broadridge Financial, BrightSphere Investment Group, CMS Energy Corp, Lancaster Colony Corp, Rogers Communications Inc, Sanofi, Apple, Atlassian Corporation, United States Steel Corp, Corp, Adtalem Global, Homes, DXC Technology Company, Eastman Chemical Company, Gen, Post Holdings, America, Columbia Sportswear Company, Exxon Mobil Corp, Chevron Corporation, Myers Squibb Co, CIGNA Corp, Regeneron Pharmaceuticals, Charter Communications, AON, Cboe, Dwight, Banco Santander, Jim Cramer's Charitable, CNBC, Apple Vision, Getty Locations: China, East, United States, Europe, Cleveland, Alexandria, California, Corning, Canadian Pacific, Teradyne, TER, Novo, Hanover, PBI, Skechers U.S.A, Bristol, Chile

☆ Stocks making the biggest moves premarket: Coinbase, TKO Group, United Airlines, D.R. Horton and more
▼ + stars: | 2024-01-23 | by ( Brian Evans | ) www.cnbc.com time to read: +5 min

The company sees earnings per share ranging between 60 and 65 cents, well below an LSEG estimate of 72 cents per share. Horton — Shares of the home construction company slipped more than 5% after first-quarter earnings per share missed Wall Street estimates. Horton earned $2.82 per share, while analysts polled by LSEG expected a profit of $2.88 per share. Analysts expected earnings of 80 cents per share, according to LSEG. Analysts expected a profit of $1.24 per share on revenue of $19.7 billion.

Persons: Truist, Enphase, Goldman Sachs, Glen Santangelo, D.R, Horton —, Horton, LSEG, Halliburton, FactSet's StreetAccount, groundings, Johnson — Johnson, Johnson, RTX, CNBC's Hakyung Kim, Samantha Subin, Jesse Pound, Lisa Kailai Han, Fred Imbert Organizations: JPMorgan, General Electric, Energy, Federal, 3M, Goldman, Teva Pharmaceutical Industries, pharma, Jefferies, Logitech —, Logitech, Wall Street, United Airlines –, United Airlines, LSEG, Boeing, Max, Barstool Sports, Netflix, Johnson, Verizon, Procter, Gamble, RTX Corporation, Wall

☆ Stocks making the biggest moves midday: United Airlines, TKO Group, 3M, Alibaba and more
▼ + stars: | 2024-01-23 | by ( Samantha Subin | ) www.cnbc.com time to read: +5 min

United Airlines – The airline stock popped nearly 5% a day after the company reported higher-than-expected earnings and revenue for the fourth quarter. TKO Group – Shares of TKO Group Holdings rallied 15.8% after announcing a deal to air its WWE flagship program known as "Raw" on Netflix next year. Revenue topped expectations, but earnings fell 6 cents short of analysts' expectations, per LSEG. Verizon posted $1.08 in adjusted earnings per share on $35.13 billion in revenue, while analysts surveyed by LSEG forecasted $1.07 per share in earnings and $34.64 billion of revenue. Procter & Gamble posted mixed results for its fiscal second quarter , topping earnings expectations but falling short on revenue.

Persons: Alibaba, Alibaba's, Truist, Coinbase – Coinbase, Goldman Sachs, Jefferies, Lockheed Martin, Horton –, Halliburton – Halliburton, Johnson – Johnson, Wall, Gamble, RTX, Zions Bancorporation, Yun Li, Sarah Min, Alex Harring Organizations: United Airlines –, Boeing, Max, Group, WWE, Netflix, LSEG, New York Times, Sunnova Energy, Enphase Energy, Federal Reserve, JPMorgan, Reuters, CSI China Internet, General Electric, GE, Teva Pharmaceutical, Teva Pharmaceuticals, Lockheed, Logitech –, Logitech, Barstool Sports, Johnson, Verizon –, Verizon, Procter, FactSet Locations: Alibaba –, China, fundaments

Tuesday's analyst calls include upgrades to two solar names and a downgrade to a key crypto stock. 7:05 a.m.: Citi increases Meta price target ahead of earnings Meta shares have more runway ahead, according to Citi. Analyst Kenneth Worthington downgraded the crypto exchange to underweight from neutral, reiterating his price target of $80. Analyst Jordan Levy upgraded Sunnova to buy from hold and raised his price target to $18 from $10. He upgraded Enphase Energy to buy from hold, moving his price target to $145 from $85.

Persons: Truist, Ronald Josey, Josey, — Pia Singh, TD Cowen, Jason Gabelman, Gabelman, Jefferies, Glen Santangelo, Teva, Cantor Fitzgerald, C.J, Muse, Kenneth Worthington, Worthington, Coinbase, — Fred Imbert, Jordan Levy, Levy Organizations: CNBC, Enphase Energy, Federal Reserve, JPMorgan, Citi, Meta, Exxon, Chevron, Cowen, Exxon Mobil, Teva Pharmaceuticals, Jefferies Investors, pharma, mdc, Nvidia, Energy, Sustainability Locations: buybacks, Teva, Monday's

☆ Stocks making the biggest moves midday: Foot Locker, Okta, Carnival, Shopify and more
▼ + stars: | 2023-11-27 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Carnival — Shares added 1% after being upgraded to buy from hold by Melius Research . Crown Castle — The telecommunications stock jumped nearly 4% following an activist push for change at Crown Castle. Shares of Crown Castle are down 20% this year. Okta — Shares of the software company dropped 3% Monday after JMP Securities downgraded Okta to market perform. Teva Pharmaceuticals — U.S.-traded shares jumped 3% after an upgrade from UBS to buy from neutral.

Persons: Locker, Josh Weinstein, Melius, Okta, JMP, Albemarle —, Etsy, TD Cowen, —, Alex Harring, Hakyung Kim, Sarah Min, Michelle Fox, Jesse Pound, Darla Mercado Organizations: Citi, Melius Research, Crown, Elliott Investment Management, Sunday, JMP Securities, Albemarle, Battery Tech, U.S, Teva Pharmaceuticals —, UBS, Xenon Pharmaceuticals, —, Adobe Analytics Locations: Crown, Albemarle

— Lisa Kailai Han 7:07 a.m. — Lisa Kailai Han 6:48 a.m. "At current levels, we believe the risk/reward skews to the downside," wrote analyst Paul Lejuez. — Lisa Kailai Han 6:05 a.m. — Lisa Kailai Han

Persons: Robert Ford Aguilar, Aguilar, Lisa Kailai Han, Rachel Vatnsdal, GeoMx, Vatnsdal, skews, Paul Lejuez, — Lisa Kailai Han, Nik Modi, Raymond James, Matt Roberts, headwinds, Roberts, Ashwani Verma, Verma, Morgan Stanley, Micron Morgan Stanley, Joseph Moore's, Moore, Amit Mehrotra, Mehrotra, Sangita Jain, Jain, Fred Imbert Organizations: CNBC, Monday, UBS, Teva Pharmaceutical, Bloom Energy, Bank of America, Arcos Dorados Bank of America, Arcos Dorados, ARCO, JPMorgan downgrades, JPMorgan, U.S, District, Prognosys, 10X Genomics, Citi, RBC, RBC Capital Markets, UBS downgrades Jazz Pharmaceuticals, Jazz Pharmaceuticals, Digital, Micron, Western, Deutsche Bank, BE Locations: America, Caribbean, Argentine, Delaware, NSTG, U.S, Europe, Mondelez, narcolepsy

☆ Stocks making the biggest moves premarket: Okta, Foot Locker, Crown Castle and more
▼ + stars: | 2023-11-27 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Teva Pharmaceutical — Shares gained 2.4% following an upgrade from UBS to buy from neutral. Mondelez — Shares rose 1.1% after RBC upgraded the snack maker to outperform from sector perform, citing share gains, category growth and expanding retail footprint. Foot Locker — The shoe-and-apparel retailer retreated 3.6% on the heels of a downgrade to sell from neutral by Citi. E-commerce stocks — Shares ticked up across the board on Cyber Monday. GE HealthCare Technologies — GE HealthCare Technologies shares fell 3% following a downgrade.

Persons: Jefferies, Elliott Management, Elliott, Locker, —, Alex Harring, Sarah Min Organizations: Teva Pharmaceutical, UBS, Wall Street Journal, RBC, Citi, Etsy, Ebay, Walmart, GE HealthCare Technologies

☆ A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free
▼ + stars: | 2023-10-24 | by ( Filip De Mott | ) www.businessinsider.com time to read: +4 min

Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.

Persons: Roche, Roivant, —, Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan

☆ Premarket stocks: What the Israel-Hamas war means for US markets
▼ + stars: | 2023-10-17 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +7 min

New York CNN —Growing unrest in the Middle East has cast a shadow on global financial markets. Israeli stocks listed in New York and Tel Aviv have sunk to recent lows, underscoring the growing economic uncertainties in the war-torn region and leaving investors unsure of where markets go from here. Funds in the US hold more than $43 billion in Israeli stocks and bonds, according to a Bloomberg tracker. Big names, big exposure: As the war continues, businesses with headquarters, factories and inventory in Israel appear increasingly at risk to geopolitical turmoil. “If the war remains confined between Israel and Palestinians, it’s likely that the markets will forget about it after a few days,” he wrote.

Persons: ”, Steven Schoenfeld, Jamie Dimon, “, Benjamin Netanyahu, Raffi Boyadjian, Sam Stovall, Nathaniel Meyersohn, drugstores, David Silverman, Bill Ford, Vanessa Yurkevich, Ford, Jim Farley, Shawn Fain Organizations: CNN Business, Bell, New York CNN, Nasdaq, Funds, Bloomberg, Hamas, Bank of Israel, JPMorgan, Israel Innovative Technology, Mobileye, Tower Semiconductor, Teva Pharmaceutical, XM, CVS, Walgreens, Walmart, Fitch, Ford Motor Company, United Auto Workers, Big Three, UAW, Monday, Ford Locations: New York, Tel Aviv, New Jersey, Israel, United States, Canada, China, Ukraine, Kippur, Kuwait, Kansas City, drugstores, Rouge, Dearborn , Michigan

Oct 9 (Reuters) - Shares in U.S. and European-listed companies with business exposure to Israel fell on Monday on worries that an escalation in conflict with Palestinian Islamist group Hamas would impact their operations. Wall Street opened lower, while European stocks dipped as surging oil prices fanned inflation worries and investors fled to the safety of government bonds and the dollar. U.S. shares of Israeli chipmaker Tower Semiconductor fell 5.2%, while Intel (INTC.O) dipped 1.1% and Nvidia (NVDA.O) 2.1%, dragging the chip sector lower. U.S.-listed shares of Israel's Teva Pharmaceutical (TEVA.TA), the world's largest generic drugmaker, fell 3.3%, while those in fertilizer group ICL Group (ICL.TA) dipped 1.4%. U.S. exchange-traded funds exposed to Israel such as the iShares MSCI Israel ETF and the ARK Israel Innovative Technology ETF fell 6.6% and 4.4%, respectively.

Persons: Benjamin Netanyahu, Raffi Boyadjian, Energean, Adani Ports, Danilo Masoni, Sruthi Shankar, Amanda Cooper, Deborah Kyvrikosaios, Arun Koyyur Organizations: Palestinian, Semiconductor, Intel, Nvidia, Energy, Tel Aviv ., U.S, Cruise Line Holdings, Royal Caribbean Group, XM, Israel's, ICL, ARK Israel Innovative Technology, Adani, Thomson Locations: Israel, Tel Aviv, Saudi Arabia, Gaza, London, India, Adani, Haifa Port, Northern Israel

☆ Stocks making the biggest moves midday: Tesla, Nike, Carnival, Nvidia and more
▼ + stars: | 2023-09-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Tesla — Stock in the electric vehicle company added 1.5% in midday trading Friday. Canaccord Genuity reiterated a buy rating on the EV stock on Thursday ahead of vehicle deliveries data. Elsewhere, Citi remained neutral on Tesla and reduced its vehicle delivery forecast to 450,000 from 468,500. Bumble — The online dating platform added 3% after Loop Capital Markets upgraded the stock to buy from hold. Corcept Therapeutics — Shares slumped 17% in midday trading as the firm contends with ongoing litigation against Teva Pharmaceuticals.

Persons: Elon Musk, Canaccord Genuity, Tim Wentworth, Roz Brewer, Bumble —, Cushing, Teva, — CNBC's Pia Singh, Alex Harring, Michelle Fox, Hakyung Kim, Darla Mercado Organizations: U.S, Senate, Intelligence, Capitol, Washington , D.C, Citi, Barclays, Anheuser, Busch InBev — U.S, LSEG, Cruise, Wonder Group, Nvidia —, Blackwell, Nvidia, Nike —, Nike, Walgreens, Bloomberg, Therapeutics, Teva Pharmaceuticals, Texas, Northcoast Research Locations: Washington ,

☆ Amoxicillin shortage: A new season of infections is here, but the shortage of a common kids’ antibiotic never ended
▼ + stars: | 2023-09-22 | by ( Brenda Goodman | ) edition.cnn.com time to read: +7 min

Respiratory illness season is coming up, and that’s going to be a huge issue,” said David Margraf, a pharmaceutical research scientist with the University of Minnesota’s Resilient Drug Supply Project. During a drug shortage, allocation helps ensure that no single buyer can claim all the available supply. Khazanchi and his colleague Dr. Ryan Brewster recently studied the clinical effects of last winter’s amoxicillin shortage. “Drug shortages will likely continue to increase if the pricing dynamics in the marketplace are not addressed,” Sandoz said in a statement. “The companies refuse to tell us what’s going on,” said Erin Fox, who tracks drug shortages at the University of Utah.

Persons: —, earaches, ”, David Margraf, Selena Ko, Erin Hooley, pediatricians, Rohan Khazanchi, Khazanchi, Ryan Brewster, Amoxicillin, ” Khazanchi, “ It’s, ” Sandoz, Erin Fox, Laura Bray, They’re, ” Margraf, ” Bray, Dr, Sanjay Gupta, “, Matt Christian Organizations: CNN, Food, University of, Project, Rush University Medical Center, Chicago Tribune, TNS, Getty, FDA, Brigham & Women’s Hospital, Teva Pharmaceuticals, Novartis, University of Utah, Angels, CNN Health, US Department of Agriculture, Pharmacopeia’s Medicines Locations: Chicago, Boston

Sept 6 (Reuters) - Bristol Myers Squibb (BMY.N) has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it should have faced generic competition. A spokesperson for Bristol Myers did not immediately respond to a request for comment. Pomalyst is a top seller for Bristol Myers, bringing in nearly $3.5 billion out of $46.16 billion of its total revenue last year. The drug was developed by Celgene, a company acquired by Bristol Myers in 2019. The generic companies, which are also named as defendants in the lawsuit, did not immediately respond to requests for comment.

Persons: Pomalyst, Bristol Myers, Celgene, Brendan Pierson, Alexia Garamfalvi, Bill Berkrot Organizations: Bristol Myers Squibb, Louisiana, Pomalyst, Bristol, Celgene, U.S . Patent, Teva Pharmaceutical Industries, Aurobindo Pharma, Breckeridge Pharmaceutical, Natco Pharma, Thomson Locations: Manhattan, New York

☆ The ADHD drug market is already stretched thin. Now it's facing a back-to-school supply strain
▼ + stars: | 2023-08-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc. Adderall and alternative ADHD medications apart from other drugs are Schedule 2 controlled substances. Production limitationsEnding the shortages of Adderall and other ADHD medications is no easy task. That means increasing the production of one drug could potentially require reducing production — and potentially impacting supply — of another drug, according to Ergun. That includes Aytu BioPharma, which makes an ADHD drug that used to be in shortage.

Persons: Jb Reed, It's, Erin Fox, they've, David Margraf, Margraf, drugmakers, Ozlem Ergun, Ergun, Novartis's, Michael Ganio, ASHP's Ganio, RJ Sangosti, Josh Disbrow, Fox Organizations: Shire Plc, Jb, Bloomberg, Getty, and Drug Administration, CNBC, University of Utah, American Society of Health, System Pharmacists, Centers for Disease Control, University of Minnesota's, Infectious Disease, Northeastern University, Teva Pharmaceuticals, Amneal Pharmaceuticals, Sandoz, Purdue Pharma, Rhodes Pharmaceuticals, Drug, Fox, Pharmacists, Drug Enforcement Administration, MediaNews, Denver, FDA, DEA Locations: U.S, Commerce City , Colorado

☆ Teva Pharmaceuticals to pay $225 mln to settle price-fixing charges
▼ + stars: | 2023-08-21 | by ( ) www.reuters.com time to read: 1 min

The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen/File Photo Acquire Licensing RightsAug 21 (Reuters) - Teva Pharmaceuticals will pay a fine of $225 million over five years to settle the criminal price-fixing charges brought against Teva in 2020 by the U.S. Department of Justice, the company said on Monday. Reporting by Pratik Jain in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

Persons: Amir Cohen, Pratik Jain, Shailesh Organizations: Teva Pharmaceutical Industries, REUTERS, Teva Pharmaceuticals, Teva, U.S . Department of Justice, Thomson Locations: Tel Aviv, Israel, Bengaluru

☆ Teva to pay $225 million in fines and divest generic drug to resolve price-fixing charges
▼ + stars: | 2023-08-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Drugmaker Teva Pharmaceuticals agreed to pay $225 million in criminal fines over five years and divest its version of a generic cholesterol drug to resolve charges related to price-fixing on that medication and other widely used treatments, the Department of Justice announced Monday. Teva, in a press release Monday, said it will pay $22.5 million each year from 2024 through 2027, and $135 million in 2028. Glenmark Pharmaceuticals will pay $30 million to resolve similar charges. Since 2020, the DOJ's antitrust division has charged five other pharmaceutical companies for participating in similar schemes affecting several generic drugs. Teva has also agreed to donate $50 million worth of two generic drugs affected by price-fixing to humanitarian organizations that provide medications to Americans in need.

Persons: Drugmaker, Teva, Jonathan Kanter, Glenmark, Apotex Organizations: Drugmaker Teva Pharmaceuticals, Department of Justice, Glenmark Pharmaceuticals, Antitrust Division, DOJ, Eastern District of Pennsylvania, Apotex Corp Locations: Eastern District

☆ Teva to pay $225 mln, divest cholesterol drug to settle price-fixing charges
▼ + stars: | 2023-08-21 | by ( ) www.reuters.com time to read: +2 min

The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen/File Photo Acquire Licensing RightsAug 21 (Reuters) - Teva Pharmaceutical (TEVA.TA) will pay $225 million and divest its copycat version of a cholesterol drug as part of its settlement of price-fixing charges, the U.S. Department of Justice said on Monday. Glenmark will also pay a penalty of $30 million to resolve similar charges, the DOJ said. Teva and Glenmark will have to divest their respective versions of a generic cholesterol drug, pravastatin, that was a core part of the companies' price-fixing conspiracy, the DOJ said. As part of the deals with the DOJ, Glenmark and Teva both admitted to participating in fixing the price of pravastatin.

Persons: Amir Cohen, Teva, Glenmark, Pratik Jain, Shailesh Organizations: Teva Pharmaceutical Industries, REUTERS, Teva Pharmaceutical, U.S . Department of Justice, Prosecutors, Pharmaceuticals, DOJ, Thomson Locations: Tel Aviv, Israel, Bengaluru

Search resuls for: "Teva Pharmaceutical"

25 mentions found